Kornimate/medical-research-clean huggingface dataset:
morphological, structural and functional neural substrates of quality of life in schizophrenia

Conditions: Schizophrenia

Summary: the aim of the investigators analysis is to identify the neural correlates of quality of life scores in schizophrenia. for this, the investigators will constitute group of patients according to their quality of life scores and the investigators will analyze their differences in patterns of brain structures and activations.


Eligibility criteria:
inclusion criteria: * diagnosis of schizophrenia according to the diagnostic and statistical manual of mental disorders (dsm-iv) criteria (american psychiatric association(apa), 1994), * age over 18 years, * informed consent to participate in the studies * french as native language exclusion criteria: * diagnosis other than schizophrenia on axis i of dsm-iv, * decompensated organic disease and mental retardation
treatment efficacy for drug abuse and aids prevention - 2

Conditions: Cocaine-Related Disorders; Heroin Dependence

Summary: the purpose of this study is to assess the safety and effectiveness of buprenorphine for treatment of concurrent intravenous heroin and cocaine dependence.


Eligibility criteria:
please contact site for information.
hpa axis study in adults

Conditions: Atopic Dermatitis; Eczema

Summary: a multicenter, open-label study to evaluate the adrenal suppression potential of mapracorat 0.1% ointment in adults with atopic dermatitis.

assessment of safety, efficacy, pharmacokinetics and adrenal suppression potential of mapracorat 0.1% ointment in adults with atopic dermatitis.

Eligibility criteria:
inclusion criteria: * signed written informed consent * male or female subject aged \>= 18 years * diagnosis of atopic dermatitis according to hanifin and rajka criteria * investigator's global assessment (iga) score of 3 (moderate) to 4 (severe) at baseline * normal acth response before start of treatment exclusion criteria: * pregnancy or lactation * clinically relevant disease, which could interfere with the study conduct or the evaluation and interpretation of the study results * concomitant medical or dermatological disorder(s), which could interfere with the study conduct or the evaluation and interpretation of the study results * clinically manifest immunosuppressive disorder or known history of malignant disease
managing insulin with a voice ai

Conditions: Medication Adherence

Summary: this study randomizes participants to have their basal insulin titrated either through standard of care or by receiving prompts through interactions with an ai-enabled smart speaker device. the primary objective of this study is to investigate the feasibility of an ai-enabled smart speaker device and whether such a device facilitates insulin titration management, increases insulin adherence and decreases time to optimal insulin dose. the secondary objective of the study is to explore whether the device improves glycemic control as defined by improvements in fasting blood sugar.


Eligibility criteria:
inclusion criteria: * patients with type 2 diabetes * patients clinically indicated to be taking daily long-acting insulin * patients currently taking long-acting insulin but necessitating active dose adjustments exclusion criteria: * patients who do not speak english * patients who do not own a smart phone * patients who do not have stable wireless internet connection at home

Keywords: voice assistant medication management insulin management smart speaker ai artificial intelligence autonomous prescriptions
detection of exhaled methane levels in hemorrhagic shock

Conditions: Hemorrhagic Shock; Trauma

Summary: this prospective observational study aims to test the efficacy of the continuous measurement of exhaled methane levels in monitoring the hemodynamic state of severely injured, bleeding trauma patients.

this prospective observational study aims to test the efficacy of the continuous measurement of exhaled methane levels in monitoring the hemodynamic state of severely injured, bleeding trauma patients. our inclusion criteria require an age of 18 years or greater, an injury severity score (iss) of 16 or greater, transport directly from scene, intubation on scene or upon arrival, hemorrhage confirmed with efast or ct, and signed consent from patient surrogates. exhaled methane concentrations and indicators of blood loss and shock (vital signs: systolic blood pressure, heart rate; blood gas and laboratory markers: base deficit, lactate, hemoglobin, hematocrit; videomicroscopic image of sublingual microcirculation) will be recorded in pre-determined time points during the first 72 in-hospital hours. the relation between exhaled methane levels and indicators of shock will constitute our primary outcome measures. the association of methane concentrations with clinical outcomes (transfusion need, mortality) will serve as secondary outcomes.

Eligibility criteria:
inclusion criteria: * injury severity score (iss)≥16 * intubated on scene or upon arrival * transported directly from scene to the emergency department of the university of szeged * hemorrhage confirmed with efast or ct * consent signed by patient surrogate

Keywords: shock hemorrhagic methane
a study of the onset and offset of antiplatelet effects comparing ticagrelor, clopidogrel, and placebo with aspirin

Conditions: Coronary Artery Disease

Summary: the purpose of this study is to see how ticagrelor, a new oral reversible anti-platelet medication, affects platelets. anti-platelet agents are medications that block the formation of blood clots by preventing the clumping of platelets. blood clots prevent us from bleeding, but when they form inside the arteries their formation is linked to a risk of medical problems such as heart attack and stroke. this study investigated how long it takes for ticagrelor to begin working and how long it takes for it to stop working after the last dose of drug. ticagrelor will be compared to clopidogrel, an established anti-platelet treatment for preventing blood clots, and placebo plus aspirin.


Eligibility criteria:
inclusion criteria: * documented stable coronary artery disease (stable angina, previous mi history, previous history of revascularization); * females of child bearing potential must have a negative pregnancy test prior to receiving study drug and be willing to use a hormonal contraceptive in addition to double barrier contraception exclusion criteria: * history of acute coronary syndromes within 12 months of screening or need for revascularization (angioplasty or coronary artery bypass graft (cabg)) * history of liver or kidney disease * have increased bleeding risk, eg, recent gastrointestinal bleed, uncontrolled high blood pressure, low platelet count, recent major trauma * history of intolerance or allergy to aspirin or clopidogrel

Keywords: coronary artery disease cad heart attack stable angina stable coronary artery disease
pep005 gel - biological effects in actinic keratosis assessed by histology

Conditions: Actinic Keratosis

Summary: this trial will be conducted to explore the biological effects in the skin following treatment with pep005 gel, 0.05% administered for two consecutive days, assessed by histology.


Eligibility criteria:
inclusion criteria: 1. male or female patients at least 18 years of age 2. patients with ak lesions within a contiguous 25 cm2 area on the upper extremity 3. patients with a 25 cm2 area of normal skin on the upper inner arm 4. female subjects must be of either non-childbearing potential or childbearing potential, provided there is a confirmed negative urine pregnancy test prior to exposure, to rule out pregnancy 5. female subjects of childbearing potential must be willing to consent to using high effective methods of contraception 6. ability to follow study instructions and likely to complete all study requirements 7. obtained written informed consent prior to any study-related procedures exclusion criteria: 1. location of the selected treatment areas within 5 cm of an incompletely healed wound within 10 cm of a suspected basal cell carcinoma (bcc) or squamous cell carcinoma (scc) 2. history or evidence of skin conditions other than the study indication that would interfere with evaluation of the study medication 3. clinical diagnosis/history or evidence of any medical condition that would expose a subject to an undue risk of a significant ae or interfere with assessments of safety, as determined by investigator clinical judgment. 4. anticipated need for in-patient hospitalisation or in-patient surgery during the study period. 5. current participation in any other interventional clinical trial 6. subjects who have received treatment with any non-marketed drug product within the last two months 7. subject known or, in the opinion of the investigator, is unlikely to comply with the clinical study protocol 8. females who are pregnant, of child-bearing potential and wishing to become pregnant during the trial, or are breast feeding 9. undergone cosmetic or therapeutic procedures within 2 cm of the selected treatment areas in the 2 weeks prior to the screening visit 10. use of acid-containing therapeutic products within 2 cm of the selected treatment areas in the 2 weeks prior to the screening visit 11. use of topical salves/topical steroids: within 2 cm of the selected treatment areas in the 2 weeks prior to the screening visit 12. treatment with immunomodulators, cytotoxic drugs or interferon/interferon inducers, systemic medications that suppress the immune system or uvb in the last 4 weeks 13. treatment with 5-fu, imiquimod, diclofenac, or photodynamic therapy: within 2 cm of the selected treatment areas within 8 weeks prior to any screening visit 14. use of systemic retinoids
effects of mobile medicine on cancer patients

Conditions: Cancer Pain

Summary: with the existing medical system and insufficient medical resources in china, we developed a mini program. a pain management mini app can be useful and appreciated by patients and health care professionals, making it a good choice for the management of cancer pain in our country . our study want to develop and test the mini program for pain management among chinese cancer patients in or discharged from hospital treatment.

healthcare interventions delivered via personal mobile device have been shown to be acceptable to users, who have identified benefits such as convenience, access to personalized information, greater awareness of own health. integrating mini program into the cancer pain care may be an effective strategy to improve cancer pain patients self-management. to design, construct, and test the mini program in patients managing cancer pain, evaluate the total remission rate of pain and the improvement in medicine compliance to improve pain management for cancer pain patients, and assess patient acceptance of the mini program.

Eligibility criteria:
inclusion criteria: * patients aged 18 years or older; * be able to read chinese and use a mobile phone; * histologically or cytologically confirmed solid tumor; * diagnosed chronic cancer pain * could understand the study process and evaluation, agreed to participate in the trial, and signed the informed consent form. exclusion criteria: * illiterate person; * incompetence; * inability to complete the pain assessment; * participation in any other therapies or other study protocols that may have an impact on pain intensity, which were the main outcomes of this study.

Keywords: mini program self management cancer pain
efficacy and safety of ad-mscs plus calpocitriol ointment in patients with moderate to severe psoriasis

Conditions: Mesenchymal Stromal Cells; Psoriasis; Drug Effect; Drug Toxicity

Summary: the purpose of this study is to evaluate the efficacy and safety of adipose derived mesenchymal stem cells (ad-mscs) plus calpocitriol ointment with moderate to severe psoriasis. any adverse events related to ad-mscs infusion will be monitored.the primary outcome is the reduction rate of pasi(psoriasis area and severity index) and treatment response will be computed from pasi before and after treatment.


Eligibility criteria:
inclusion criteria: 1. moderate to severe psoriasis vulgaris ( pasi \> 10 or bsa \>10%) 2. 18 to 65 years old 3. written/signed informed consent exclusion criteria: 1. guttate psoriasis, inverse psoriasis or exclusively associated with the face 2. acute progressive psoriasis, and erythroderma tendency 3. current (or within 1 year) pregnancy or lactation 4. current significant anxiety or depression with the self-rating anxiety scale (sas) \> 50 or the self-rating depression scale (sds) \> 53, or with other psychiatric disorders 5. with history of primary cardiovascular, respiratory, digestive, urinary, endocrinologic and hematologic diseases, which can't be controlled through ordinary treatments. those who with malignant diseases, infections, electrolyte imbalance, acid-base disturbance. patients with clinical test results listed below: abnormal serum calcium level ( ca2+ \> 2.9 mmol/l or \< 2 mmol/l);ast or alt 2 times more than normal upper limit; creatinine and cystatin c more than normal upper limit; hemoglobin elevates 20g/l more than normal upper limit,or hemoglobin reduction to anemia; platelet count less than 75.0\*10\^9/l; white blood cell less than 3.0\*10\^9/l; or any other abnormal laboratory test results, assessed by investigators, that are not suitable for this clinical study 6. patients with malignant tumors, or when they were enrolled with abnormal tumor markers or with other organ dysfunction 7. allergy to anything else ever before; 8. current registration in other clinical trials or participation within a month; 9. topical treatments (i.e. corticosteroids or retinoic acid or vitamin d analogs ) within 2 weeks; systemic therapy or phototherapy (ultraviolet radiation b,uvb) and psoralen combined with ultraviolet a (puva) within 4 weeks; biological therapy within 12 weeks; 10. medical conditions assessed by investigators, that are not suitable for this clinical study.
prospective, randomized study evaluating the efficacy of chlorhexidine gluconate impregnated no-rinse cloths.

Conditions: Osteoarthritis; Infection

Summary: subjects in the study were randomized to a treatment group using chlorhexidine cloths or a standard-of-care group who only had a bath with antibacterial soap and water. both groups received standard infection control practices during admission.

between march 2012 and november 2012, patients scheduled for total hip arthroplasty (tha) or total knee arthroplasty (tka) were randomized (539 patients; 554 arthroplasties) at the time of their preoperative clinic visit. patients in the chlorhexidine protocol group (275 arthroplasties) applied 2% chlorhexidine gluconate-impregnated cloths to their skin the night before and the morning of surgical admission. patients in the standard of care group (279 arthroplasties) took a bath with soap and water the night before surgical admission. both groups were subject to standard infection control practices during admission. the primary outcome was periprosthetic infection incidence within one year of surgery, and secondary outcomes included the potential influence of risk factors for periprosthetic infection and incidence of adverse events.

Eligibility criteria:
inclusion criteria: * joint replacement surgery for any reason * 18 years or older exclusion criteria: * unable to comply with study requirements * were pregnant * were under the age of 18 years * medical history of immunosuppression or systemic disease e.g. human immunodeficiency virus, status-post organ transplantation * received greater than 10 milligrams of prednisone equivalent for more than 10 days within 90 days prior to enrollment; * chronic hepatitis b or c infection * had an infection in or around the joint requiring surgery.

Keywords: infection; arthroplasty; chlorhexidine; hip; knee
a clinical trial of anti-angiogenic drug combination tl-118 for pancreatic cancer patients who are starting gemcitabine treatment

Conditions: Metastatic Pancreatic Cancer

Summary: tl-118 is an anti-angiogenic drug combination designed for the treatment of cancer. the investigational product tl-118 comprises of four well-known active components. the therapy is administrated at a unique dosing regimen that was found to be effective and advantageous in terms of safety. the product is formulated as an oral suspension, conveniently administrated by the patients at home and not requiring medical staff assistance. this phase ii clinical trial aims to evaluate the efficacy, safety and tolerability of tl-118 in gemcitabine treated pancreatic cancer patients


Eligibility criteria:
inclusion criteria: 1. age at least 18 years at enrollment. 2. metastatic pancreatic cancer 3. the patient has histologically or cytologically confirmed pancreatic adenocarcinoma. 4. patient has measurable disease by (recist). 5. patient is starting standard of care gemcitabine treatment 6. ecog performance status ≤ 1 7. adequate renal function 8. adequate hepatic function 9. adequate bone marrow reserve 10. resolution of prior therapy acute adverse events. 11. patient is capable of swallowing. 12. patient's informed consent. - exclusion criteria: 1. hypersensitivity to one or more of the tl-118 active components 2. known glucose-6-phosphate-dehydrogenase deficiency (g6pd). 3. cns or brain metastases 4. prior systemic therapy for pancreas cancer 5. subjects who received any investigational medication, prior local therapy for pancreas cancer , or any significant change in treatment within 1 month prior to screening 6. concurrent use of any other investigational product 7. subjects with a clinically significant or unstable medical condition that would preclude safe and complete study participation 8. use of supplements or complementary medicines/botanicals, except for conventional multivitamin supplements, calcium, selenium and soy supplements. 9. patient has known historical or active infection with hiv, hepatitis b, or hepatitis c 10. circumstances likely to interfere with absorption of orally administrated drugs. 11. history of noncompliance to medical regimens or coexisting -
3d thyroid education model for student

Conditions: Satisfaction, Personal

Summary: the purpose of our study is to develop a high-fidelity thyroid education model, that can be utilized for medical students/ pgy doctors/ residents training. this model can help them better understand the structure of thyroid, learn about what are thyroid nodules, and practice thyroid fine needle aspiration examination with the model. the investigators would also evaluate the efficacy of using this model in student teaching.

background： thyroid nodular disorder is prevalent in endocrine clinics, and while thyroid fine needle aspiration examination is crucial for evaluating nodules, conveying the procedure to students is challenging. the investigators propose a high-fidelity 3d model to enhance education, especially for hands-on practice. our study aims to assess the model's education efficacy. study design： this is a prospective study. methods： in our study, 3d scanning and 3d printing technology will be used to create the thyroid high-fidelity model. the investigators plan to choose 3d printing materials that enable the practice of thyroid fine needle aspiration produce with no.22 or no.23 needles. effect： the investigators hope to assist students understand the structure of thyroid and thyroid nodules better. and students will be able to practice thyroid fine needle aspiration examination with the 3d high-fidelity model. the outcome of our study may be utilized in medical schools or hospitals to facilitate student education. key words： 3d printing; medical education model; high-fidelity simulation; thyroid; fine needle aspiration

Eligibility criteria:
inclusion criteria: * medical students, medical interns, pgy physicians, and resident physicians training at fu jen catholic university hospital exclusion criteria: * refused to participate in the study

Keywords: 3d printing medical education model high-fidelity simulation thyroid fine needle aspiration
effects of physical training in inph

Conditions: Hydrocephalus, Normal Pressure

Summary: patients with idiopathic normal pressure hydrocephalus (inph) have variable difficulties regarding gait, balance, cognition and micturition. a shunt operation will improve these difficulties in most cases. data suggest however, that they do not change their physical activity postoperatively. physical training has been shown to be beneficial in patients with similar diseases i.e. parkinson. the aim of this study is to apply a high intensity physical training program after a shunt operation to see if the patients can improve their physical capacity and ambulatory activity more than patients who only receive standardized written advice about physical training.

consecutive patients with inph at the neurological departments of university hospital of linköping and at sahlgrenska university hospital are included and randomized for either physical training according to a validated training concept for elderly and cognitive impaired patients named hife ( high intensity functional exercise) together with a standardized written instruction for home training of physical exercises or only a standardized written instruction for home training. goal attainment scaling will be used to set measurable goals together with the patient. the training will take place in a facility where physiotherapists are available either at the two centers or close to the patient´s home.those physiotherapists at the centers responsible for the training will contact and send the local physiotherapists a manual and give instructions about the hife concept and will also stay in contact for the whole intervention i.e. 12 weeks ( one hour two times a week). a minimum of 18 out of 24 session will be required.

Eligibility criteria:
inclusion criteria: shunt-operated patients with idiopathic normal pressure hydrocephalus diagnosed according the international guidelines from 2005 exclusion criteria: mmse: equal to and below 16 and/or inability to walk, with or without support , for 10 m. other disease, e.g severe heart disease, asthma making intensive physical training impossible.

Keywords: exercise therapy